12:08 PM EDT, 07/14/2025 (MT Newswires) -- Gilead Sciences ( GILD ) said Monday that new data from its twice-yearly HIV prevention drug Yeztugo, or lenacapavir, showed effectiveness and tolerability across diverse populations in phase 3 trials.

The populations include pregnant and lactating women and adolescents, groups often underrepresented in past HIV prevention studies, according to the company.

Gilead said that trial participants preferred the twice-yearly injection over daily oral medication, citing increased confidence in not missing doses and feeling more protected.

The US Food and Drug Administration approved Yeztugo in June.

Shares of the company were up 1.6% in recent trading.

Price: 111.37, Change: +1.72, Percent Change: +1.57